Stockscreener 앱 받기
1.56
7.59%
0.11
시장 영업 전:
1.58
0.02
+1.28%
Coherus Oncology Inc 주식(CHRS)의 최신 뉴스
Coherus Oncology, Inc. Financial Disclosures & Filings - TradingView
Free cash flow per share of Coherus Oncology, Inc. – SWB:8C5 - TradingView
Enterprise value to EBITDA forward of Coherus Oncology, Inc. – NASDAQ:CHRS - TradingView
CHRS Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBITDA forward of Coherus Oncology, Inc. – LS:A12ETZ - TradingView
CHRS Should I Buy - Intellectia AI
Coherus Oncology, Inc. Actuals & Estimates (NASDAQ:CHRS) - TradingView
8C5 Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of Coherus Oncology, Inc. – NASDAQ:CHRS - TradingView
Price to sales forward of Coherus Oncology, Inc. – NASDAQ:CHRS - TradingView
Coherus Oncology (CHRS) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Coherus Oncology (CHRS) Proxy filing Summary - Quartr
Coherus Oncology (CHRS) Enters Clinical Collaboration for Phase 1 Trial - GuruFocus
Coherus Enters Trial Collaboration, Supply Agreement With Zumutor Biologics - marketscreener.com
Coherus and Zumutor announce phase 1 cancer trial collaboration - Investing.com
Coherus and Zumutor announce phase 1 cancer trial collaboration By Investing.com - Investing.com India
Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi) - The Manila Times
Coherus Oncology and Zumutor Biologics Announce Phase 1 Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI - Quiver Quantitative
Coherus and Zumutor Biologics Announce Clinical - GlobeNewswire
Coherus doses first patient in cancer combo trial with Zumutor - Stock Titan
Coherus Oncology (CHRS) Slides Amid Sector Weakness, Testing Key Support LevelsBox Spread - dars.gov.et
COHERUS ONCOLOGY INC (CHRS) Stock Chart - ChartMill
Coherus Oncology, Inc. 8-K SEC Filing June 12, 2026 – Entity Information, Common Stock, NASDAQ, and Exhibit Letter from Ernst & Young LLP 18205556 – Minichart - Minichart
Coherus Oncology appoints PwC as new auditor, replaces Ernst & Young - Investing.com Australia
[8-K] Coherus Oncology, Inc. Reports Material Event - Stock Titan
Coherus Oncology (CHRS) director receives 30K RSUs and 60K stock option grant - Stock Titan
[Form 4] Coherus Oncology, Inc. Insider Trading Activity - Stock Titan
CHRS: Immuno-oncology pipeline advances with key data and global deals expected in 6–18 months - TradingView
CHRS News | COHERUS ONCOLOGY INC (NASDAQ:CHRS) - ChartMill
CHRS Q1 2026 Earnings: Narrower-Than-Expected Loss Despite Negative Stock ReactionEarnings Surprise Report - newsline.com
Coherus Oncology (CHRS) CFO receives repriced $1.59 stock options, cancels higher-strike grants - Stock Titan
Coherus (NASDAQ: CHRS) reprices 3.2M CEO stock options to $1.59 - Stock Titan
Coherus Biosciences Announces 2026 Stockholder Meeting Results - The Globe and Mail
Coherus Oncology, Inc. 8-K SEC Filing: Company Details, Stock Information, and Compliance Disclosures (May 27, 2026) - Minichart
Coherus Oncology shareholders approve director elections and equity plan changes - Investing.com Canada
Coherus Oncology shareholders approve director elections and equity plan changes By Investing.com - Investing.com South Africa
Coherus Oncology (CHRS) shareholders approve equity plan changes and option repricing - Stock Titan
Coherus Oncology (CHRS) reports Q1 loss, lags revenue estimates - MSN
TD Cowen Maintains Coherus Oncology(CHRS.US) With Buy Rating - Moomoo
Coherus Oncology (CHRS) AGM 2026 Summary - Quartr
CHRS: All proposals passed except the stock option price reduction, which was adjourned - TradingView
CHRS: Directors and key proposals were approved; stock option vote adjourned to May 29, 2026 - TradingView
CHRSCoherus Oncology Inc Stock Price and Quote - Finviz
Coherus Oncology Inc. (CHRS) Rises 2.55%: Key Levels to Watch After Support HoldETF AUM Growth - newsline.com
Coherus Oncology (CHRS) Holds Above Support After Modest GainNAAIM Exposure - newsline.com
Coherus BioSciences stock (US19247A1007): short interest remains elevated as investors watch oncolog - Ad-hoc-news.de
Coherus Oncology (CHRS) Q1 2026 earnings summary - Quartr
Coherus Oncology Q1 earnings call highlights - MSN
What Does The Future Hold For Coherus Oncology, Inc. (NASDAQ:CHRS)? These Analysts Have Been Cutting Their Estimates - 富途牛牛
Coherus BioSciences stock (US19247A1007): earnings reset and oncology focus after Humira biosimilar - AD HOC NEWS
Earnings call transcript: Coherus BioSciences Q1 2026 revenue miss prompts cautious outlook By Investing.com - Investing.com Australia
Earnings call transcript: Coherus BioSciences Q1 2026 revenue miss prompts cautious outlook - Investing.com UK
0.05%
0.74%
자본화:
|
볼륨(24시간):